Abstract
Background. Statins are the recently evolved agents that aid in periodontal regeneration and ultimately in attaining periodontal health. Atorvastatin (ATV) and Simvastatin (SMV) are specific competitive inhibitors of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. The current study was conducted to compare the effectiveness of 1.2% ATV and 1.2% SMV, in addition to scaling and root planing (SRP), in the treatment of intrabony defects in subjects with chronic periodontitis.Methods. Ninety-six individuals were categorized into three treatment groups: SRP plus 1.2% ATV, SRP plus 1.2% SMV and SRP plus placebo. Clinical parameters of full-mouth plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), and relative attachment level (RAL) were recorded at baseline before SRP and at 3, 6 and 9 months. Bone fill was assessed using percentage radiographic defect depth reduction at baseline, 6 months and 9 months.Results. Both ATV and SMV showed significant PD reduction and RAL gain than placebo. ATV group showed greater mean PD reduction and mean RAL gain as compared to SMV group at 3, 6 and 9 months. Furthermore, ATV group sites exhibited a significantly greater percentage of radiographic defect depth reduction (33.23 ± 3.11%; 34.84 ± 3.07%) as compared to SMV (30.39 ± 3.36%; 32.15 ± 3.37%) at 6 and 9 months.Conclusion. ATV resulted in greater improvements in clinical parameters with higher percentage of radiographic defect depth reduction as compared to SMV in the treatment of intrabony defects in CP subjects.
Highlights
IntroductionChronic periodontitis (CP) is a multi-factorial infectious disease that occurs as a result of the host immune inflammatory response to pathogenic microorganisms, leading to the destruction of periodontal tissues, bone resorption and tooth loss.[1]
The current study was conducted to compare the effectiveness of 1.2% ATV and 1.2% SMV, in addition to scaling and root planing (SRP), in the treatment of intrabony defects in subjects with chronic periodontitis
ATV resulted in greater improvements in clinical parameters with higher percentage of radiographic defect depth reduction as compared to SMV in the treatment of intrabony defects in Chronic periodontitis (CP) subjects
Summary
Chronic periodontitis (CP) is a multi-factorial infectious disease that occurs as a result of the host immune inflammatory response to pathogenic microorganisms, leading to the destruction of periodontal tissues, bone resorption and tooth loss.[1]. Inhibitors of 3-hydroxy-3-glutarylcoenzyme A reductase, like simvastatin (SMV) and atorvastatin (ATV), are widely used to lower cholesterol in patients with hyperlipidemia and arteriosclerosis.[4,5] Apart from lipid-lowering properties, statins possess dynamic properties like antiinflammatory effects as shown by reduction in MMP-9 and TNF-α levels.[6] They are thought to increase angiogenesis and bone formation as recognized by expression of bone anabolic factors such as vascular endothelial growth factor and bone morphogenic protein-2,7,8 promising increased bone regeneration. Atorvastatin (ATV) and Simvastatin (SMV) are specific competitive inhibitors of 3-hydroxy-2-methylglutaryl coenzyme A reductase. The current study was conducted to compare the effectiveness of 1.2% ATV and 1.2% SMV, in addition to scaling and root planing (SRP), in the treatment of intrabony defects in subjects with chronic periodontitis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
